top of page


Calder is a preclinical-stage biopharmaceutical company with a pipeline focused on the discovery, development, and commercialization of subunit protein-stabilized vaccine bioprocesses for universal influenza headless hemagglutinin, respiratory syncytial virus (RSV), and Epstein-Barr virus EBV unmet needs.


The following pipeline outlines these three areas of focus and indication targets for these areas.

Screenshot 2023-01-05 at 4.56.20 PM.png
bottom of page